首页> Lung cancer: Journal of the International Association for the Study of Lung Cancer> Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

导出原文传递

翻译打印收藏纠错

第一作者： Martin Reck

作者： Martin Reck ^[1] ; Luis Paz-Ares ^[2] ; Paolo Bidoli ^[3] ; Federico Cappuzzo ^[4] ; Shaker Dakhil ^[5] ; Denis Moro-Sibilot ^[6] ; Hossein Borghaei ^[7] ; Melissa Johnson ^[8] ; Robert Jotte ^[9] ; Nathan A. Pennell ^[10] ; Frances A. Shepherd ^[11] ; Anne Tsao ^[12] ; Michael Thomas ^[13] ; Gebra Cuyun Carter ^[14] ; Faye Chan-Diehl ^[15] ; Ekaterine Alexandris ; Pablo Lee ; Annamaria Zimmermann ; Andreas Sashegyi ; Maurice Pérol

作者单位： Eli Lilly and Company ^[1] Rocky Mountain Cancer Centers ^[2] Ospedale S Gerardo ^[3] Thoracic Oncology Unit Teaching Hospital A Michallon ^[4] Cancer Center of Kansas ^[5] Department of Thoracic Oncology, Airway Research Center North (ARCN), Member of the German Center ^[6] Istituto Toscano Tumori-Ospedale-Civile-Livorno ^[7] Fox Chase Cancer Center ^[8] Léon-Bérard Cancer Center ^[9] Sarah Cannon Research Institute ^[10] Princess Margaret Cancer Centre ^[11] Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universit?tsklinikum Heidelberg ^[12] Virgen del Rocio University Hospital ^[13] University of Texas MD Anderson Cancer Center ^[14] Cleveland Clinic Taussig Cancer Institute ^[15]

关键词 Human monoclonal antibody Non-small cell lung cancer (NSCLC)Ramucirumab Refractory patients Vascular endothelial growth factor (VEGF)Docetaxel Clinical trial Histology Angiogenesis Phase 3 clinical trial

发布时间 2018-05-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交